Amgen Revives Defunct Drug as Old Therapies Seek New Cure

Amgen Inc.’s experimental drug rilotumumab, set aside by the company after it disappointed in a study, has been revived after a fresh look at data in gastric cancer found it helped a group of patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.